ACTU Stock — Actuate Therapeutics Inc.: Cash, EV, Pipeline

Share price

$0.98

Market cap

$23.6M

Cash

$4.4M

Enterprise value

$19.2M

Balance sheet

Cash	$4.4M
Debt	$0.0M
Net cash	$4.4M
Enterprise value	$19.2M
Basic shares	24.0M shares
Fully diluted shares	30.4M shares
Fully diluted market cap	$29.8M
Cash per share	$0.18

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading ACTU daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Feb 11 - Mar 25	FOLFIRNINOX	Phase 2	Pancreatic Adenocarcinoma; Pancreatic Adenocarcinoma Metastatic	—
Aug 12 - Sep 23	Elraglusib Oral Tablets	Phase 2	Advanced Malignant Solid Tumor	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Elraglusib

Phase 2 · Active Modality: small molecule

Target GSK-3β (glycogen synthase kinase-3 beta)

Partnerships UIC / Northwestern University: exclusive license (origin of compound); Incyte: investigator-initiated trial combining elraglusib with retifanlimab (PD-1) + mFOLFIRINOX in mPDAC

Indications

metastatic pancreatic ductal adenocarcinoma (mPDAC), first-line (Phase 2)
Ewing sarcoma (pediatric) (Stage not disclosed)
neuroblastoma (pediatric) (Stage not disclosed)
recurrent/refractory pediatric solid cancers (Phase 1)
advanced cancer (Stage not disclosed)

Catalysts

— first half of 2026

Status note Lead product candidate: small-molecule GSK-3β inhibitor. IV formulation: Phase 2 Actuate-1801 Part 3B in first-line mPDAC (elraglusib+GnP vs GnP); FDA/EMA meetings planned 1H 2026 to discuss Phase 3 registration design; Phase 1/2 Actuate-1902 in pediatric R/R solid cancers identified Ewing sarcoma and neuroblastoma for further development. Oral tablet formulation: IND filed April 2026 for Phase 1/2 in advanced cancer (funding-dependent); Phase 1b investigator-initiated trial (UPMC) with retifanlimab + mFOLFIRINOX started August 2025.

Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Elraglusib Oral Tablets
Lead indication	Advanced Malignant Solid Tumor
Lead phase	Phase 2
Active trials	2
Collaborator trials	3

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07714395	Phase 2	Not yet recruiting	Sponsor	ACTU	—	Advanced Malignant Solid Tumor	—
NCT03678883	Phase 2	Active, not recruiting	Sponsor	ACTU	—	Cancer; Pancreatic Cancer; Sarcoma	—
NCT05077800	Phase 2	Active, not recruiting	Collaborator	Colin D. Weekes, M.D., PhD	—	Pancreatic Adenocarcinoma; Pancreatic Adenocarcinoma Metastatic	—
NCT05010629	Phase 2	Active, not recruiting	Collaborator	Glenn J. Hanna	—	Salivary Gland Cancer; Recurrent Salivary Gland Cancer; Metastatic Cancer	—
NCT06896188	Phase 1	Recruiting	Collaborator	Anwaar Saeed	—	Pancreatic Adenocarcinoma	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 3 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 5 active trials for Actuate Therapeutics Inc. on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

ACTU — Actuate Therapeutics Inc.